| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10952998 | AZURITY | Amlodipine formulations |
Oct, 2037
(13 years from now) | |
| US11364230 | AZURITY | Amlodipine formulations |
Oct, 2037
(13 years from now) | |
| US11701326 | AZURITY | Amlodipine formulations |
Oct, 2037
(13 years from now) | |
| US10894039 | AZURITY | Amlodipine formulations |
Oct, 2037
(13 years from now) | |
| US11471409 | AZURITY | Amlodipine formulations |
Oct, 2037
(13 years from now) | |
| US10959991 | AZURITY | Amlodipine formulations |
Oct, 2037
(13 years from now) | |
| US11484498 | AZURITY | Amlodipine formulations |
Oct, 2037
(13 years from now) | |
| US10695329 | AZURITY | Amlodipine formulations |
Oct, 2037
(13 years from now) | |
| US10799453 | AZURITY | Amlodipine formulations |
Apr, 2039
(14 years from now) | |
Katerzia is owned by Azurity.
Katerzia contains Amlodipine Benzoate.
Katerzia has a total of 9 drug patents out of which 0 drug patents have expired.
Katerzia was authorised for market use on 08 July, 2019.
Katerzia is available in suspension;oral dosage forms.
Katerzia can be used as a method of treating hypertension, angina, method of treating hypertension.
The generics of Katerzia are possible to be released after 11 April, 2039.
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: Method of treating hypertension; A method of treating hypertension; Angina
Dosage: SUSPENSION;ORAL
KATERZIA family patents
